menu
    • menu
    [{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab duocarmazine","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Byondis \/ Not Applicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SYD1875","moa":"5T4","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ Not Applicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ Not Applicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab duocarmazine","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ Syneos Health"},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Trastuzumab Duocarmazine","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ Not Applicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Glycotope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Byondis \/ Byondis","highestDevelopmentStatusID":"3","companyTruncated":"Byondis \/ Byondis"},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Tastuzumab Duocarmazine","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ Not Applicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"(vic-) Trastuzumab Duocarmazine","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ Not Applicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"(vic-) Trastuzumab Duocarmazine","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Medac","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ Medac"},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BYON3521","moa":"c-Met","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ Not Applicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"(vic-) Trastuzumab Duocarmazine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Byondis

    Menu

    Byondis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : (vic-) Trastuzumab Duocarmazine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            U.S. Food and Drug Administration Issues Complete Response Letter for Byondis' [Vic-]Trastuzumab Duocarmazine

                            Details : SYD985 ([vic-]trastuzumab duocarmazine) is an anti-HER2 antibody-drug conjugate (ADC) which is being developed for HER2-positive unresectable locally advanced or metastatic breast cancer (MBC).

                            Brand Name : SYD985

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 15, 2023

                            Lead Product(s) : (vic-) Trastuzumab Duocarmazine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BYON3521

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Byondis Initiates Phase I Study of Next Generation Antibody-Drug Conjugate BYON3521

                            Details : BYON3521.001 intends to evaluate safety, PK and preliminary efficacy of BYON3521 in up to 150 patients aged 18 or over with histologically confirmed c-MET-expressing, MET-amplified or MET-mutated (except exon 14 mutated) locally advanced or metastatic so...

                            Brand Name : BYON3521

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 25, 2022

                            Lead Product(s) : BYON3521

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : (vic-) Trastuzumab Duocarmazine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Medac

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EMA Validates Marketing Authorization Application for Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metas...

                            Details : Antibody part of SYD985 (trastuzumab duocarmazine) binds to HER2 on surface of cancer cell and the ADC is internalized by cell. After proteolytic cleavage of linker, the inactive cytotoxin is activated and DNA damage is induced, resulting in tumor cell d...

                            Brand Name : SYD985

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 18, 2022

                            Lead Product(s) : (vic-) Trastuzumab Duocarmazine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Medac

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : (vic-) Trastuzumab Duocarmazine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Accepts Byondis' Biologics License Application for [Vic-] Trastuzumab Duocarmazine (SYD985) in HER2-Positi...

                            Details : SYD985 ((vic-) trastuzumab duocarmazine) ,met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement of 2.1 months over PC. TULIP also demonstrated supportive overall survival (OS) results.

                            Brand Name : SYD985

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 12, 2022

                            Lead Product(s) : (vic-) Trastuzumab Duocarmazine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tastuzumab Duocarmazine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Byondis ESMO Late-Breaking Presentation Confirms ADC [Vic-] Trastuzumab Duocarmazine (SYD985) Superior to Phys...

                            Details : Pivotal Phase III TULIP® Study Showed [Vic-] Trastuzumab Duocarmazine (SYD985) Provided 2.1 month increase in progression-free survival compared to standard treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic ...

                            Brand Name : SYD985

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 19, 2021

                            Lead Product(s) : Tastuzumab Duocarmazine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Glycotope

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Byondis , Glycotope Enter Platform Access Agreement Discovery and Development

                            Details : Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs). Specific financial terms have not been disclose...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 27, 2021

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Glycotope

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trastuzumab Duocarmazine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Byondis Announces Positive Topline Results of Pivotal Phase III TULIP® Study in Patients With HER2-Positive U...

                            Details : The Phase III TULIP study “SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer” met its primary endpoint of progression-free survival, demonstrating a statistically significant improvement ove...

                            Brand Name : SYD985

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 08, 2021

                            Lead Product(s) : Trastuzumab Duocarmazine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trastuzumab duocarmazine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Syneos Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Byondis Intends to Bag Commercialisation Partner for Breast Cancer ADC by 2H21

                            Details : Byondis is drafting plans to pursue commercialisation partners for when results from its Phase III breast cancer antibody-drug conjugate study are released in 2Q21.

                            Brand Name : SYD985

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 16, 2020

                            Lead Product(s) : Trastuzumab duocarmazine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Syneos Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trastuzumab duocarmazine,Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Byondis Initiates Phase I Study of ADC [Vic-]Trastuzumab Duocarmazine + Niraparib in HER2-Expressing Solid Tum...

                            Details : First patients have started treatment in a Phase I study of its investigational antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) in combination with niraparib in patients with a HER2-expressing locally advanced or metastatic solid tu...

                            Brand Name : SYD985

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 25, 2020

                            Lead Product(s) : Trastuzumab duocarmazine,Niraparib Tosylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed

                            Byondis

                            Netherlands arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SYD1875

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Byondis Initiates Phase I Study of Antibody-Drug Conjugate SYD1875

                            Details : The First-in-Human Dose-Escalation and Expansion Study with the Antibody-Drug Conjugate SYD1875 will evaluate the safety, pharmacokinetics and preliminary efficacy of SYD1875 in patients with 5T4-expressing.

                            Brand Name : SYD1875

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 11, 2020

                            Lead Product(s) : SYD1875

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth